SCHEMBL6690653

SCHEMBL6690653

NC(=O)C(Cc1ccc(O)cc1)N1C(=O)c2ccccc2C1=O

nearest known ligand 0.81

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.81
POLB P06746 3/20 0.81
L3MBTL1 Q9Y468 2/20 0.81
GAA P10253 1/20 0.61
KMT2A Q03164 4/20 0.56
MEN1 O00255 3/20 0.56
CYP2D6 P10635 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
SMN1; SMN2 Q16637 2/20 0.51
PKM P14618 1/20 0.51
AADAT Q8N5Z0 1/20 0.49
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
LMNA P02545 1/20 0.48
MAPT P10636 1/20 0.48
TSHR P16473 1/20 0.48
HSD11B1 P28845 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5506018 0.89 ALDH1A1 (1.00) ALDH1A1POLBL3MBTL1GAAKMT2A
SCHEMBL4800642 0.89 ALDH1A1 (1.00) ALDH1A1POLBL3MBTL1GAAKMT2A
SCHEMBL4797064 0.89 ALDH1A1 (1.00) ALDH1A1POLBL3MBTL1GAAKMT2A
SCHEMBL6692611 0.87 POLB (1.00) ALDH1A1POLBL3MBTL1GAAKMT2A
SCHEMBL11463170 0.87 POLB (1.00) ALDH1A1POLBL3MBTL1GAAKMT2A
SCHEMBL13919525 0.83 POLB (0.76) ALDH1A1POLBL3MBTL1GAAKMT2A
SCHEMBL4467004 0.83 POLB (0.76) ALDH1A1POLBL3MBTL1GAAKMT2A
SCHEMBL22513798 0.78 ALDH1A1 (0.69) ALDH1A1POLBL3MBTL1GAACYP2D6
SCHEMBL29159229 0.77 ALDH1A1 (0.76) ALDH1A1POLBL3MBTL1GAAKMT2A
SCHEMBL29159234 0.77 ALDH1A1 (0.76) ALDH1A1POLBL3MBTL1GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1477486-A2 Imides as inhibitors of TNF alpha CELGENE CORPORATION (US) 2004-11-17 EP claimed
EP-0706521-A1 NOVEL IMIDES CELGENE CORPORATION (US) 1996-04-17 EP claimed
WO-1995001348-A2 IMIDES AS INHIBITORS OF TNP ALPHA CELGENE CORPORATION (US) 1995-01-12 WO claimed
EP-1477486-A2 Imides as inhibitors of TNF alpha CELGENE CORPORATION (US) 2004-11-17 EP disclosed
EP-0706521-B1 IMIDES AS TNF ALPHA INHIBITORS CELGENE CORP (US) 2002-10-02 EP disclosed
US-6200987-B1 ADMINISTERING AS TUMOR NECROSIS FACTOR INHIBITORS; CACHEXIA, ENDOTOXIN SHOCK; RETROVIRUS VIRICIDES CELGENE CORPORATION 2001-03-13 US disclosed
US-6075041-A TUMOR NECROSIS FACTOR CELGENE CORPORATION (US) 2000-06-13 US disclosed
EP-1004581-A2 Process for the preparation of thalidomide CELGENE CORPORATION (US) 2000-05-31 EP disclosed
EP-1004572-A2 Amines as inhibitors of TNF alpha CELGENE CORPORATION (US) 2000-05-31 EP disclosed
EP-1004580-A2 Imides as inhibitors of TNF alpha CELGENE CORPORATION (US) 2000-05-31 EP disclosed
US-5877200-A Cyclic amides CELGENE CORPORATION (US) 1999-03-02 US disclosed
US-5698579-A INHIBITOR OF TUMOR NECROSIS FACTOR CELGENE CORPORATION (US) 1997-12-16 US disclosed
US-5605914-A INHIBITORS OF TUMOR NECROSIS FACTOR CELGENE CORPORATION (US) 1997-02-25 US disclosed
EP-0706521-A1 NOVEL IMIDES CELGENE CORPORATION (US) 1996-04-17 EP disclosed
US-5463063-A Preparation of thalidomide; inhibitor of tumor necrosis factor CELGENE CORPORATION (US) 1995-10-31 US disclosed
WO-1995001348-A2 IMIDES AS INHIBITORS OF TNP ALPHA CELGENE CORPORATION (US) 1995-01-12 WO disclosed